Purpose of this Study
We are doing this study to compare the effectiveness of atezolizumab + a multi-kinase inhibitor (either cabozantinib or lenvatinib) versus a multi-kinase inhibitor alone.
Who Can Participate?
Eligibility
Adults who:
- Have hepatocellular carcinoma (a type of liver cancer)
- Received exactly 1 previous line of therapy, which must have been atezolizumab + bevacizumab
For more information about who can join this study, please contact the study team at john.d.gibbs@duke.edu.
- Have hepatocellular carcinoma (a type of liver cancer)
- Received exactly 1 previous line of therapy, which must have been atezolizumab + bevacizumab
For more information about who can join this study, please contact the study team at john.d.gibbs@duke.edu.
What is Involved?
If you choose to join this study, you will:
- Take one of the study drugs, either cabozantinib or lenvatinib, by mouth once per day
- Receive the study drug atezolizumab through an IV once every 3 weeks (if assigned)
- Return to the clinic every 3 weeks so we can monitor your health
- Give blood and urine for testing
- Get CT or MRI scans every 9 weeks
You may be on the study drugs for up to 2 years.
- Take one of the study drugs, either cabozantinib or lenvatinib, by mouth once per day
- Receive the study drug atezolizumab through an IV once every 3 weeks (if assigned)
- Return to the clinic every 3 weeks so we can monitor your health
- Give blood and urine for testing
- Get CT or MRI scans every 9 weeks
You may be on the study drugs for up to 2 years.
Study Details
Full Title
[ACCRU-GI-2008] A Phase II Randomized Study of Atezolizumab plus Multi-Kinase Inhibitor versus Multi-Kinase Inhibitor Alone in Subjects with Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab
Principal Investigator
Aman
Opneja
Protocol Number
PRO00110227
NCT ID
NCT05168163
Phase
II
Enrollment Status
OPEN TO ACCRUAL